Monthly Prescribing Reference

Emactuzumab Fast Tracked for Tenosynovial Giant Cell Tumor

Results from a phase 1 trial showed the independently reviewed best overall objective response rate was 71% in emactuzumab-treated patients. The Food and Drug Administration (FDA) has granted Fast ...
Business Wire

U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S ...

Mom had her leg amputated after cancer diagnosis. Now she’s undergoing another ‘high risk’ procedure after tumors were found on her spine

Sam Butler has been battling giant cell tumors since 2020 ...
Medscape

FDA Approves Vimseltinib for Tenosynovial Giant Cell Tumors

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not ...
BioWorld

Deciphera’s Romvimza wins FDA nod for tenosynovial giant cell tumors

Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral CSF1R inhibitor vimseltinib, newly branded Romvimza, could take significant ...
ascopubs.org

Racial disparities in tenosynovial giant cell tumor: An analysis of the Surveillance, Epidemiology and End Results database.

Analysis of trends in race and gender disparities in the incidence of osteosarcoma, leiomyosarcoma, and Ewing sarcoma from 2000 to 2021. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...